Oryon Splashes Onto Parkinson’s Scene With $42M for Cell Therapy

Oryon Cell Therapies’ lead cell therapy is an autologous treatment designed to replace dopaminergic neurons in patients with Parkinson’s disease. Phase 1b/2a data showed that the asset can improve motor function and mobility in patients.

Scroll to Top